These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8502958)

  • 1. [Bone and myeloma].
    Ravaud P; Roux C
    Rev Prat; 1993 Feb; 43(3):293-7. PubMed ID: 8502958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of bisphosphonate on myeloma bone disease].
    Abe M; Matsumoto T; Kosaka M
    Rinsho Ketsueki; 2002 May; 43(5):349-52. PubMed ID: 12096484
    [No Abstract]   [Full Text] [Related]  

  • 3. [Multiple myeloma and bone manifestations. Role of clodronate].
    Bauduer F; Delmer A
    Bull Cancer; 1996 Jul; 83(7):542-7. PubMed ID: 8868941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumour activity of bisphosphonates in human myeloma cells.
    Shipman CM; Rogers MJ; Apperley JF; Graham R; Russell G; Croucher PI
    Leuk Lymphoma; 1998 Dec; 32(1-2):129-38. PubMed ID: 10037008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the understanding of myeloma bone disease and tumour growth.
    Yaccoby S
    Br J Haematol; 2010 May; 149(3):311-21. PubMed ID: 20230410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates--mechanisms of action in multiple myeloma.
    Shipman CM; Rogers MJ; Vanderkerken K; Van Camp B; Graham R; Russell G; Croucher PI
    Acta Oncol; 2000; 39(7):829-35. PubMed ID: 11145441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone lesions in patients with multiple myeloma].
    Umeda M; Takata M; Tsubuku M
    Nihon Naika Gakkai Zasshi; 1995 Jul; 84(7):1070-4. PubMed ID: 7561360
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis.
    Clézardin P; Gligorov J; Delmas P
    Joint Bone Spine; 2000 Jan; 67(1):22-9. PubMed ID: 10773965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guidelines for the use of bisphosphonates in multiple myeloma: Recommendations of the expert committee of the Spanish Myeloma Group from the PETHEMA group].
    García-Sanz R; Alegre A; Capote FJ; Hernández JM; Rosiñol L; Rubia Jde L; Sureda A; Arriba Fd; Bargay J; Díaz Mediavilla J; García-Laraña J; Lahuerta JJ; Mateos MV; Prósper F; San Miguel J; Bladé J;
    Med Clin (Barc); 2010 Mar; 134(6):268-78. PubMed ID: 19863972
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma.
    Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK
    Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in the treatment of malignant bone disease.
    Berenson JR; Lipton A
    Annu Rev Med; 1999; 50():237-48. PubMed ID: 10073275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloma bone disease: pathogenesis, current treatments and future targets.
    Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
    Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in vitro osteoclast-forming assay to measure myeloma cell-derived osteoclast-activating factors.
    Zannettino AC; Farrugia AN; To LB; Atkins GJ
    Methods Mol Med; 2005; 113():245-56. PubMed ID: 15968108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of myeloma with bisphosphonates.
    Bataille R
    N Engl J Med; 1996 Feb; 334(8):529-30. PubMed ID: 8559209
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic approaches to myeloma bone disease: an evolving story.
    Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
    Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New agents in the Treatment of Myeloma Bone Disease.
    Ring ES; Lawson MA; Snowden JA; Jolley I; Chantry AD
    Calcif Tissue Int; 2018 Feb; 102(2):196-209. PubMed ID: 29098361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evidence-Based Approach to Myeloma Bone Disease.
    Bingham N; Reale A; Spencer A
    Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.